Study of Lidocaine and Dexmedetomidine Infusion to Reduce Pain, Inflammation, and Oxidative Stress After Laparoscopic Bariatric Surgery in Adults with Obesity

What this Trial Is About

Researchers are evaluating whether giving a combination of intravenous lidocaine and dexmedetomidine LIDEX during laparoscopic bariatric surgery can reduce post-operative pain, inflammation, and oxidative stress in adults with obesity. This randomized clinical trial compares four groups lidocaine alone, dexmedetomidine alone, the combination LIDEX, and a saline placebo. The study aims to understand which approach best controls pain and lowers inflammatory and oxidative markers after surgery. Participants receive an intravenous infusion of their assigned study drugs during surgery, from the induction of anesthesia until skin closure. Four groups are studied lidocaine infusion, dexmedetomidine infusion, the LIDEX combination in one syringe, and a saline placebo infusion. No post-operative infusions are given. Blood samples are collected before surgery, immediately after, and three hours postoperatively to measure inflammatory cytokines and oxidative stress markers. During the study, pain is evaluated 24 hours after surgery using the International Pain Outcomes Questionnaire IPOQ. Researchers continuously monitor heart rate and blood pressure for safety, with predefined rescue steps if needed. Participants are expected to stay in the hospital for at least 24 hours post-surgery. The study will assess patient-reported pain, blood biomarkers, and safety measures to determine the effects of the treatments.

Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.